Copyright
©The Author(s) 2015.
World J Gastroenterol. Sep 28, 2015; 21(36): 10443-10452
Published online Sep 28, 2015. doi: 10.3748/wjg.v21.i36.10443
Published online Sep 28, 2015. doi: 10.3748/wjg.v21.i36.10443
Figure 1 Flow chart of the treatment scheme.
PFS: Progression free survival; ORR: Objective response rate; DCR: Disease control rate; HAIC: Hepatic arterial infusion chemotherapy; PVA: Polyvinyl alcohol particles; BCLC: Barcelona Clinic Liver Cancer staging.
Figure 2 Comparison of the median progression free survival in the chemoembolization + hepatic arterial infusion chemotherapy treatment group (group B) and chemoembolization alone treatment group (group A).
HAIC: Hepatic arterial infusion chemotherapy.
Figure 3 Comparison of the median progression free survival in patients with different BCLC stages and patient state in the chemoembolization + hepatic arterial infusion chemotherapy treatment group (group B) and chemoembolization alone treatment group (group A).
A: Hepatocellular carcinoma (HCC) patients with BCLC stage A/B disease; B: HCC patients with BCLC stage C disease; C: HCC patients without vessel invasion; D: HCC patients with vessel invasion. HAIC: Hepatic arterial infusion chemotherapy.
-
Citation: Gao S, Zhang PJ, Guo JH, Chen H, Xu HF, Liu P, Yang RJ, Zhu X. Chemoembolization alone
vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. World J Gastroenterol 2015; 21(36): 10443-10452 - URL: https://www.wjgnet.com/1007-9327/full/v21/i36/10443.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i36.10443